CGEM — Cullinan Therapeutics Share Price
0.000.00%
Last trade - 00:00- $674.41m
- $207.53m
- 31
- 28
- 95
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.49 | ||
| Price to Tang. Book | 1.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.9% | ||
| Return on Equity | -30.98% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 18.94 | n/a | n/a | 1.35 | 11.58 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Directors
- Anthony Rosenberg NEC (68)
- Nadim Ahmed PRE (53)
- Patrick Baeuerle CFD (63)
- Jeff Trigilio CFO (37)
- Leigh Zawel CSO (55)
- Raymond Keane OTH (62)
- Jennifer Michaelson OTH (54)
- Corinne Savill OTH (62)
- Thomas Ebeling IND (62)
- Ansbert Gadicke IND (63)
- Stephen Webster IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 15th, 2016
- Public Since
- January 8th, 2021
- No. of Shareholders
- 15
- No. of Employees
- 85
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 43,065,645
- Address
- One Main Street, Suite 1350, CAMBRIDGE, 02142
- Web
- https://cullinantherapeutics.com/
- Phone
- +1 6174104650
- Auditors
- KPMG LLP
Upcoming Events for CGEM
Cullinan Oncology Inc Annual Shareholders Meeting
Q2 2024 Cullinan Oncology Inc Earnings Release
Similar to CGEM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Cullinan Therapeutics share price?
As of Today at 19:06 UTC, shares in Cullinan Therapeutics are trading at $15.66. This share price information is delayed by 15 minutes.
How has the Cullinan Therapeutics share price performed this year?
Shares in Cullinan Therapeutics last closed at $15.66 and the price had moved by +49.29% over the past 365 days. In terms of relative price strength the Cullinan Therapeutics share price has outperformed the S&P500 Index by +24.23% over the past year.
What are the analyst and broker recommendations for Cullinan Therapeutics?
The overall consensus recommendation for Cullinan Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cullinan Therapeutics dividend yield?
Cullinan Therapeutics does not currently pay a dividend.
Does Cullinan Therapeutics pay a dividend?
Cullinan Therapeutics does not currently pay a dividend.
When does Cullinan Therapeutics next pay dividends?
Cullinan Therapeutics does not currently pay a dividend.
How do I buy Cullinan Therapeutics shares?
To buy shares in Cullinan Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cullinan Therapeutics?
As of the previous close price of $15.66, shares in Cullinan Therapeutics had a market capitalisation of $674.41m.
Where are Cullinan Therapeutics shares listed?
Here are the trading details for Cullinan Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CGEM
What kind of share is Cullinan Therapeutics?
Based on an overall assessment of its quality, value and momentum Cullinan Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cullinan Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Cullinan Therapeutics is $28.00. That is 78.8% above the last closing price of $15.66.
Analysts covering Cullinan Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.34 for the next financial year.
What is the trend in the Cullinan Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cullinan Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +52.29%.
As of the last closing price of $15.66, shares in Cullinan Therapeutics were trading +30.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cullinan Therapeutics PE Ratio?
The Cullinan Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cullinan Therapeutics?
Cullinan Therapeutics' management team is headed by:
- Anthony Rosenberg - NEC
- Nadim Ahmed - PRE
- Patrick Baeuerle - CFD
- Jeff Trigilio - CFO
- Leigh Zawel - CSO
- Raymond Keane - OTH
- Jennifer Michaelson - OTH
- Corinne Savill - OTH
- Thomas Ebeling - IND
- Ansbert Gadicke - IND
- Stephen Webster - IND